Patents by Inventor Yongfeng Sun

Yongfeng Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200323859
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: April 30, 2020
    Publication date: October 15, 2020
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20200199724
    Abstract: A method for desensitizing a metal alloy such as an aluminum (Al) alloy is presented. The surface of the alloy is treated by controlled laser beam irradiation. The scanning laser beam heats the alloy to reach a relative low temperature between a solvus temperature and a soften/annealing temperature of the metal alloy to controllably reduce the degree of sensitization (DOS) of the metal alloy. The locally rapid heating and cooling effects produced by scanning the laser can improve the future sensitization resistance of the metal alloy, reduce the average desensitization temperature applied, and maintain the mechanical properties of Al alloy at the same time.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Yongfeng Lu, Leimin Deng, Chenfei Zhang, Shiding Sun
  • Patent number: 10689378
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xingnian Fu, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Patent number: 10676479
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xingnian Fu, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Publication number: 20200005478
    Abstract: Provided are a measuring method and apparatus for a damaged part of a vehicle includes: acquiring an image to be processed of a vehicle; acquiring the damaged part of the vehicle in the image to be processed according to the image to be processed; acquiring first position information of key points in the image to be processed according to the image to be processed; determining a transformation relation between the image to be processed and a first fitting plane according to the key points included in the image to be processed and the first position information, where the first fitting plane is a fitting plane determined according to the key points included in the image to be processed on the 3D model; acquiring a projection area of the damaged part in the first fitting plane according to the transformation relation; and measuring the projection area to acquire a measuring result.
    Type: Application
    Filed: September 10, 2019
    Publication date: January 2, 2020
    Applicant: Baidu Online Network Technology (Beijing) Co., Ltd.
    Inventors: Yongfeng ZHONG, Xiao TAN, Feng ZHOU, Hao SUN, Errui DING
  • Publication number: 20190274962
    Abstract: The present invention relates to a preparation method for a traditional Chinese medicine drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, the present invention relates to a micro drop pill preparation method with high drug-loading capacity, simple preparation process and high production rate and a micro drop pill prepared by using the method. Specially, The drop pill preparation method used comprises the following steps: (1) material melting step: heat melting a medicine and a drop pill matrix to obtain a molten medicine liquid; (2) dropping step: delivering the molten medicine liquid to a dripper, and acquiring medicine drops of the molten medicine liquid by means of vibration dropping; and, (3) condensation step: cooling the medicine drops with a cooling gas to obtain micro drop pills.
    Type: Application
    Filed: May 24, 2019
    Publication date: September 12, 2019
    Applicant: TASLY PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Xiaobing Sun, Shunnan Zhang, Zhengliang Ye, Hai'ou Dong, Hongbo Zhang, Wensheng Zhang, Lihong Zhou, Chenming Li, Cong Chen, Xiaofeng Liu, Shiqing Wang, Changsheng Rong, Yongfeng Zheng, Lijun Fan
  • Publication number: 20190233426
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 1, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20190202828
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 4, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20190142837
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Patent number: 10220036
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 5, 2019
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Publication number: 20170348312
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 7, 2017
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Patent number: 9580437
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 28, 2017
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Publication number: 20160176882
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Patent number: D577428
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: September 23, 2008
    Inventor: Yongfeng Sun